|Bid||8.63 x 1100|
|Ask||8.81 x 1000|
|Day's Range||8.35 - 8.86|
|52 Week Range||6.99 - 11.68|
|Beta (5Y Monthly)||0.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.60|
In this article we are going to estimate the intrinsic value of Cytosorbents Corporation ( NASDAQ:CTSO ) by estimating...
Every investor in Cytosorbents Corporation ( NASDAQ:CTSO ) should be aware of the most powerful shareholder groups...
Shares of Cytosorbents Corporation (NASDAQ: CTSO) jumped 17.3% on Tuesday, spurred higher by news that the Investigational Device Exemption (IDE) request for its DrugSorb-ATR Antithrombotic Removal system has been approved by the U.S. Food and Drug Administration, allowing clinical trials of the device to move forward. Cytosorbents' DrugSorb-ATR Antithrombotic Removal device just cleared another regulatory hurdle. Exempt from certain other steps that some medical devices must go through, the company can now begin testing the device, which allows patients undergoing heart bypass surgeries to curb the amount of blood-thinning drug ticagrelor in the bloodstream during and after the procedure.